Last reviewed · How we verify
Idarubicin(IDA)
Idarubicin(IDA) is a Anthracycline topoisomerase II inhibitor Small molecule drug developed by Chinese Academy of Medical Sciences. It is currently FDA-approved for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia in blast crisis. Also known as: darubicin, IDA, Demethoxydaunor Ubicin.
Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells.
Idarubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents DNA unwinding, leading to cell death in rapidly dividing cancer cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia in blast crisis.
At a glance
| Generic name | Idarubicin(IDA) |
|---|---|
| Also known as | darubicin, IDA, Demethoxydaunor Ubicin |
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Anthracycline topoisomerase II inhibitor |
| Target | Topoisomerase II; DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Idarubicin is an anthracycline chemotherapy agent that intercalates between DNA base pairs and inhibits topoisomerase II, an enzyme essential for DNA replication and transcription. This dual mechanism causes DNA strand breaks and prevents cancer cell proliferation, ultimately triggering apoptosis. It is particularly effective against hematologic malignancies due to its ability to penetrate leukemic cells.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Chronic myeloid leukemia in blast crisis
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Cardiotoxicity (dose-dependent)
- Mucositis
- Nausea and vomiting
- Alopecia
- Hepatotoxicity
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (PHASE2)
- CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) (PHASE2)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Idarubicin(IDA) CI brief — competitive landscape report
- Idarubicin(IDA) updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI
Frequently asked questions about Idarubicin(IDA)
What is Idarubicin(IDA)?
How does Idarubicin(IDA) work?
What is Idarubicin(IDA) used for?
Who makes Idarubicin(IDA)?
Is Idarubicin(IDA) also known as anything else?
What drug class is Idarubicin(IDA) in?
What development phase is Idarubicin(IDA) in?
What are the side effects of Idarubicin(IDA)?
What does Idarubicin(IDA) target?
Related
- Drug class: All Anthracycline topoisomerase II inhibitor drugs
- Target: All drugs targeting Topoisomerase II; DNA
- Manufacturer: Chinese Academy of Medical Sciences — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute myeloid leukemia (AML)
- Indication: Drugs for Acute lymphoblastic leukemia (ALL)
- Indication: Drugs for Chronic myeloid leukemia in blast crisis
- Also known as: darubicin, IDA, Demethoxydaunor Ubicin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing